Nik Ekman, the Application Development Manager at CPC, will lead a webinar discussing crucial factors for transitioning cell therapy processes from research to commercial production. This event is scheduled for December 3, 2025, at 08:00 PST, 11:00 EST, and 16:00 GMT.
As the demand for advanced therapies continues to grow, ensuring a smooth shift from laboratory-based activities to large-scale manufacturing is vital. The webinar will emphasize the importance of establishing robust and reproducible processes that can effectively meet increasing demand. Early design considerations for flexible, enclosed workflows are essential for promoting efficiency, quality, and sterility assurance throughout the development of cell therapies.
Participants can expect to gain insights into key scaling factors relevant at each stage of the cell therapy development pipeline, from preclinical research and clinical trials to eventual commercialization. The session will also cover how designing scalable and adaptable workflows early contributes to ensuring compliance with regulatory standards later in the product lifecycle.
Another significant topic will be the role of sterile connector technology, which facilitates closed-system processing, thereby enhancing sterility assurance and minimizing risks associated with critical cell therapy procedures.
A live question-and-answer segment will follow the presentations, providing attendees with an opportunity to engage directly with the expert panelists and gain further understanding of the discussed topics.
This webinar is produced with support from GEN – Genetic Engineering and Biotechnology News.
